Research Topics
| Jean Claude BystrynSummaryAffiliation: New York University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Treatment options in pemphigusJ C Bystryn
The Ronald O Perelman Department of Dermatology, The New York University School of Medicine, New York, NY, USA
G Ital Dermatol Venereol 144:351-61. 2009....- IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgarisJean Claude Bystryn
The Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
Autoimmunity 39:601-7. 2006..The mechanism by which it does so is not known. The following study was conducted to confirm the effectiveness of IVIg for the acute control of active PV and to elucidate the mechanism by which it does... - PemphigusJean Claude Bystryn
The Ronald O Perelman Department of Dermatology, New York University School of Medicine, 560 1st Avenue, New York, NY 10016, USA
Lancet 366:61-73. 2005..Immunosupressants, anti-inflammatory drugs, and antibiotics are used as adjuvants, but apart from IVIg, these therapy options are non-specific and more research is needed to develop treatments with improved side-effect profiles... - Emerging melanoma vaccinesJean Claude Bystryn
New York University School of Medicine, The Ronald O Perelman Department of Dermatology, NYU Cancer Institute, New York, NY, USA
Expert Opin Emerg Drugs 10:393-402. 2005.... - Melanoma vaccines: what we know so farJean Claude Bystryn
The Ronald O Perelman Department of Dermatology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York, USA
Oncology (Williston Park) 19:97-108; discussion 108, 111-2, 115. 2005.... - Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodiesAnnette Czernik
Department of Dermatology, New York University School of Medicine, 550 First Ave, Tisch Hospital, H313, New York, NY 10016, USA
Arch Dermatol 144:658-61. 2008..We propose that the addition of immunosuppressive agents to the IVIg regimen may increase the ability of IVIg to lower the level of pathogenic antibodies... - Vaccines for melanomaJean Claude Bystryn
Ronald O Perelman Department of Dermatology and Melanoma Program, Melanoma Immunotherapy Clinic, Kaplan Comprehensive Cancer Center, New York University School of Medicine, 35 East 35th Street, Suite 208, New York, NY 10016, USA
Dermatol Clin 20:717-25. 2002..To establish the true effectiveness of vaccines in the treatment of malignant melanoma, several large, prospectively randomized phase III studies are currently being conducted... - Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanomaSandra R Reynolds
Department of Dermatology, New York University School of Medicine, Kaplan Comprehensive Cancer Center, New York, New York 10016, USA
Clin Cancer Res 9:657-62. 2003..The following study was conducted to examine whether these responses are associated with improved clinical outcome in melanoma vaccine-treated patients... - Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in miceDean Johnston
Hunter College School of Health Sciences, New York, NY, USA
Cancer Immunol Immunother 55:412-9. 2006..This may provide a simple, safe, and effective way to enhance the immunogenicity of vaccines that consist of pure protein antigens... - Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?Sandra R Reynolds
Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA
Int J Cancer 119:157-61. 2006..Measurement of CYT-MAA serum level during therapy could provide an intermediate marker of response in these patients... - TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccinesDean Johnston
Hunter College School of Health Sciences, New York, NY, USA
Cancer Immunol Immunother 56:1133-41. 2007..The lack of toxicity also indicates that this combination may by safe, effective method to boost immune response to cancer vaccines... - Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic miceDean Johnston
Hunter College School of Health Sciences, 425 East 25th Street, New York, NY 10010, USA
Cancer Immunol Immunother 54:345-50. 2005..Heterogeneity may hamper interpretation of vaccine immunogenicity and relevant tumor antigens in humans... - Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigusAnnette Czernik
The Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA
J Am Acad Dermatol 58:796-801. 2008..The following study was conducted to confirm observations made in a limited number of patients that suggest intravenous immunoglobulin (IVIg) may be able to selectively lower serum levels of only abnormal autoantibodies... - Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an updateAnnette Czernik
Department of Dermatology, University of California, Irvine, CA 92697 2400, USA
Autoimmunity 45:111-8. 2012.... - Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodiesMargarita Lolis
Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA
J Am Acad Dermatol 64:484-9. 2011..Intravenous immunoglobulin (IVIg)--a relatively new approach to treat pemphigus--lowers serum levels of pemphigus antibodies; however, the optimal way to use this agent is unknown... - Potential role of interleukin-17 in the pathogenesis of bullous pemphigoidSiavash Toosi
Ronald O Perelman Department of Dermatology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
Med Hypotheses 74:727-8. 2010..The information obtained could also lead to the development of novel therapeutic strategies for this and other autoimmune blistering diseases... - Why is the mortality of bullous pemphigoid greater in Europe than in the US?Jean Claude Bystryn
Ronald O Perelman Department of Dermatology, NYU School of Medicine, New York, New York, USA
J Invest Dermatol 124:xx-xxi. 2005 - Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgarisMichelle G Green
Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA
Arch Dermatol 144:1621-4. 2008..This study was conducted to study the effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antibodies against desmoglein 1 and desmoglein 3 in patients with pemphigus vulgaris... - Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanomaSandra R Reynolds
Department of Dermatology, Kaplan Comprehensive Cancer Center New York University School of Medicine, New York, New York 10016, USA
Clin Cancer Res 9:1497-502. 2003..These findings suggest that the sequential assay of tumor cells in the circulation by reverse transcription-PCR may provide an early indication of the effectiveness of cancer therapy... - Treatment of pemphigus with intravenous immunoglobulinJean-Claude Bystryn
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York 10016, USA
J Am Acad Dermatol 47:358-63. 2002..CONCLUSIONS: These results indicate that IVIg can effectively and rapidly control active pemphigus unresponsive to conventional therapy and suggest that the mechanism of its action is decreasing serum levels of intercellular antibodies... - Improved identification of potentially dangerous pigmented skin lesions by computerized image analysisMaria Jasmin Jamora
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
Arch Dermatol 139:195-8. 2003.... - Jean-Claude Bystryn 1938-2010. An obituarySergei A Grando
Department of Dermatology, University, California, Irvine, NJ, USA
Exp Dermatol 20:293-6. 2011..Dr. Bystryn was an innovative physician-scientist whose scientific contributions will be long recalled and admired both by patients and colleagues... - Reliability and convergent validity of two outcome instruments for pemphigusMisha Rosenbach
Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19119, USA
J Invest Dermatol 129:2404-10. 2009..Subset analysis suggests that for this population of mild-to-moderate disease activity, the PDAI captures more variability in cutaneous disease than the ABSIS... - Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimodCaroline Othoro
Department of Medical Parasitology, New York University Cancer Institute, School of Medicine, New York University, New York, New York 10010, USA
Infect Immun 77:739-48. 2009.... - A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesisJean-Claude Bystryn
Department of Dermatology, New York University School of Medicine, New York, New York, USA
J Am Acad Dermatol 54:513-6. 2006 - Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgarisMaria Jasmin J Jamora
Department of Dermatology, New York University School of Medicine, New York, New York, USA
J Am Acad Dermatol 48:976-7. 2003 - Sensitivity of indirect immunofluorescence and ELISA in detecting intercellular antibodies in endemic pemphigus foliaceus (Fogo Selvagem)Paulo Rowilson Cunha
Department of Dermatology, Faculty of Medicine de Jundiaí, Sao Paulo, Brazil
Int J Dermatol 45:914-8. 2006..Scientific literature certifies that both ELISA and IIF bear high sensitivity in spite of the fact that a direct comparison between the ELISA and IIF tests has never been performed... - IVI g TREATMENT OF PEMPHIGUS: how it works and how to use itJean-Claude Bystryn
Ronald O. Perelman Department of Dermatology New York University School of Medicine New York, NY
J Invest Dermatol 125:1093-8. 2005 - Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccineDean Johnston
Hunter College School of Health Sciences, 425 East 25th Street, New York NY 10010, USA
Vaccine 24:1958-65. 2006.... - Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapyPaulo Rowilson Cunha
Department of Dermatology, Faculdade de Medicina de Jundia, , Brazil
Int J Dermatol 43:682-4. 2004 - Limitations in enzyme-linked immunosorbent assays for antibodies against desmogleins 1 and 3 in patients with pemphigusJean-Claude Bystryn
Arch Dermatol 138:1252-3. 2002 - Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoidJean-Claude Bystryn
Arch Dermatol 144:946. 2008 - Kinetics of response to conventional treatment in patients with pemphigus vulgarisAnnette Czernik
Arch Dermatol 144:682-3. 2008 - Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusDedee F Murrell
Department of Dermatology at St George Hospital, University of NSW, Sydney, Australia
J Am Acad Dermatol 58:1043-6. 2008..These should assist in development of consistent reporting of outcomes in future studies... - Frequency of shifts over time in the profile of antidesmoglein antibodies in pemphigus vulgarisDaniel Weitz
Arch Dermatol 143:1073-4. 2007 - A confusing message will not improve the detection of melanomaJean-Claude Bystryn
Arch Dermatol 143:806; author reply 806-7. 2007 - Increasing ratio of thin to thick melanoma lesions: pathogenesis and early detection of this cancerJean-Claude Bystryn
Arch Dermatol 143:804; author reply 804-5. 2007 - Cutaneous pemphigus vulgaris: what causes it?Jean Claude Bystryn
J Am Acad Dermatol 55:175-6; author reply 176-7. 2006 - Can nondermatologists really recognize potentially dangerous skin lesions as well as dermatologists?Jean Claude Bystryn
Arch Dermatol 138:1378. 2002 - Oral and topical corticosteroids in bullous pemphigoidJean-Claude Bystryn
N Engl J Med 347:143-5; author reply 143-5. 2002
Research Grants
- Polypeptide Vaccine In IL-2 Liposomes For Prostate CaJean Claude Bystryn; Fiscal Year: 2002..Successful completion of this work may provide a new treatment for prostate cancer that has minimal toxicity, that improves quality of life, and that has the ultimate potential to prevent this cancer. ..
- POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMAJean Claude Bystryn; Fiscal Year: 2004..More broadly, it may provide a general method of potentiating the immunogenicity of vaccines against other cancers and to infectious diseases. ..
- PEMPHIGUS 2005-PROGRESS AND FUTURE DIRECTIONSJean Claude Bystryn; Fiscal Year: 2005..We expect it will attract 100-150 scientists and clinicians dedicated to investigate and treating pemphigus. ..
- PHASE II RANDOMIZED TRIAL OF IVIG WITH OR WITHOUT CYCLOPHOSPHAMIDE IN PEMPHIGUSJean Claude Bystryn; Fiscal Year: 2007..By improving the effectiveness of IVIg, it would also reduce the cost of this very expensive treatment and minimize its toxicity. ..
- SERUM CYT-MAA AS AN EARLY MARKER OF RESPONSE TO THERAPY IN RESECTED MELANOMAJean Claude Bystryn; Fiscal Year: 2007....